Covid-19疫苗在门诊和住院医疗环境中的有效性
该研究采用检测阴性设计,纳入2021年1月1日至6月22日多州187家医院41,552例住院和221家急诊/紧急护理机构21,522例就诊的≥50岁Covid-19样疾病成人,通过电子健康记录和免疫登记确定接种状态。全程mRNA疫苗接种(第二剂后≥14天)对实验室确诊SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91),导致ICU入住为90%(95%CI 86-93),导致急诊/紧急护理就诊为91%(95%CI 89-93)。Ad26.COV2.S疫苗对住院和急诊/紧急护理就诊的有效性分别为68%(95%CI 50-79)和73%(95%CI 59-82)。全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在85岁及以上、慢性病患者及黑人或西班牙裔成人中为81%-95%。
要点
- 全程mRNA疫苗接种(第二剂后≥14天)对≥50岁成人SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91)。
- 全程mRNA疫苗接种对SARS-CoV-2感染导致ICU入住的有效性为90%(95%CI 86-93)。
- 全程mRNA疫苗接种对SARS-CoV-2感染导致急诊或紧急护理就诊的有效性为91%(95%CI 89-93)。
- Ad26.COV2.S疫苗对住院和急诊/紧急护理就诊的有效性分别为68%(95%CI 50-79)和73%(95%CI 59-82)。
- 全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在≥85岁、慢性病患者及黑人或西班牙裔成人中为81%-95%。
适用人群与场景
- ≥50岁成人,具有Covid-19样疾病并接受SARS-CoV-2分子检测者。
- 场景包括住院(187家医院)和急诊或紧急护理就诊(221家机构),多州,2021年1月1日至6月22日。
诊断标准与关键阈值
- 全程mRNA疫苗接种定义为第二剂后≥14天。
- 采用检测阴性设计,比较接种与未接种患者SARS-CoV-2检测阳性的比值。
- 疫苗有效性经倾向性评分权重调整,并调整年龄、地理区域、日历时间(2021年1月1日至每次就诊索引日期的天数)和局部病毒流行。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:检测阴性设计研究;样本量:住院41,552例(187家医院)和急诊/紧急护理就诊21,522例(221家机构);人群:≥50岁Covid-19样疾病成人;多州,2021年1月1日至6月22日。
- 全程mRNA疫苗接种对实验室确诊SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91),导致ICU入住为90%(95%CI 86-93),导致急诊/紧急护理就诊为91%(95%CI 89-93)。
- 全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在BNT162b2和mRNA-1273疫苗间相似,在≥85岁、慢性病患者及黑人或西班牙裔成人中范围为81%-95%。
- Ad26.COV2.S疫苗对住院的有效性为68%(95%CI 50-79),对急诊/紧急护理就诊为73%(95%CI 59-82)。
证据类型、等级与局限
- 证据类型:观察性检测阴性设计研究;局限:原文未明确列出,但设计本身为观察性、非随机化。
对床旁实践的改变
- 支持≥50岁成人全程接种mRNA疫苗以预防需住院、ICU入住或急诊/紧急护理就诊的SARS-CoV-2感染;Ad26.COV2.S疫苗同样有效但有效性数值较低。
指南或共识出处
- 原文未提及指南或共识名称;研究由美国疾病控制与预防中心资助。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission to an intensive care unit (ICU), or ambulatory care in an emergency department or urgent care clinic.
METHODS: We conducted a study involving adults (≥50 years of age) with Covid-19-like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed 41,552 admissions to 187 hospitals and 21,522 visits to 221 emergency departments or urgent care clinics during the period from January 1 through June 22, 2021, in multiple states. The patients' vaccination status was documented in electronic health records and immunization registries. We used a test-negative design to estimate vaccine effectiveness by comparing the odds of a positive test for SARS-CoV-2 infection among vaccinated patients with those among unvaccinated patients. Vaccine effectiveness was adjusted with weights based on propensity-for-vaccination scores and according to age, geographic region, calendar time (days from January 1, 2021, to the index date for each medical visit), and local virus circulation.
RESULTS: The effectiveness of full messenger RNA (mRNA) vaccination (≥14 days after the second dose) was 89% (95% confidence interval [CI], 87 to 91) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization, 90% (95% CI, 86 to 93) against infection leading to an ICU admission, and 91% (95% CI, 89 to 93) against infection leading to an emergency department or urgent care clinic visit. The effectiveness of full vaccination with respect to a Covid-19-associated hospitalization or emergency department or urgent care clinic visit was similar with the BNT162b2 and mRNA-1273 vaccines and ranged from 81% to 95% among adults 85 years of age or older, persons with chronic medical conditions, and Black or Hispanic adults. The effectiveness of the Ad26.COV2.S vaccine was 68% (95% CI, 50 to 79) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization and 73% (95% CI, 59 to 82) against infection leading to an emergency department or urgent care clinic visit.
CONCLUSIONS: Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection. (Funded by the Centers for Disease Control and Prevention.).
参考来源
- Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021. PMID: 34496194. doi:10.1056/NEJMoa2110362
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。